SRx Health Solutions, Inc. 8-K

What Happened
SRx Health Solutions, Inc. (SRXH) filed an 8-K on March 3, 2026 announcing it plans a new securities offering (the “New Offering”) to sell a new series of convertible Series B preferred stock and related warrants under a New Securities Purchase Agreement. The company said certain existing investors who had participation rights under prior purchase agreements (from the July 7, 2025 note financing and the October 27/31, 2025 Series A financing) have signed limited waivers and consents permitting the New Offering and waiving their participation rights. Some of those existing investors, as Required Holders under the Series A Purchase Agreement, also consented to allow the Series B preferred to rank pari passu with the Series A preferred for dividends, distributions and liquidation preferences (limited to the Series B). A form of the waiver is filed as Exhibit 10.1.

Key Details

• Prior financings referenced: July 7, 2025 note financing (senior secured convertible notes with $7,650,000 original principal and warrants to acquire 21,338,062 common shares) and the Series A financing (Oct 31, 2025 issuance of 19,035 Series A preferred shares and 54,527,811 Series A warrants for ~ $15.23 million).
• The Series A Purchase Agreement allowed up to 38,070 Series A preferred shares for up to $30.46 million; existing investors had participation rights under Section 4(o).
• Waivers executed by certain existing investors permit the New Offering and waive those investors’ participation rights for this and any Subsequent Placement after the waiver effective date.
• The Series B terms (price, conversion, preference amounts) will be set in a certificate of designation to be filed; the waiver allows Series B to be treated as Parity Stock with Series A for certain preferences.

Why It Matters
This filing signals SRx is arranging another preferred-stock financing to raise capital. The waivers from existing investors clear a potential hurdle (their contractual participation rights) and allow new investors to buy Series B preferred and related warrants. For shareholders, new preferred shares and warrants can dilute common equity and affect priority on liquidation and dividend rights depending on the final Series B terms. Investors should watch upcoming filings for the New Securities Purchase Agreement and the Series B certificate of designation to see the exact economic and conversion terms, total proceeds, and the potential impact on common share dilution and capitalization.